abstract BACKGROUND AND OBJECTIVE: Subcutaneous immunotherapy (SCIT) is approved in the United States for the treatment of pediatric asthma and rhinitis; sublingual immunotherapy (SLIT) does not have regulatory approval but is used in clinical practice. The objective of this study was to systematically review the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis.
Asthma is one of the most common chronic diseases of childhood, affecting .6 million children in the United States. 1 Allergic rhinitis affects up to 40% of children in the United States. 2 Allergen-specific immunotherapy (SIT) is frequently used to treat asthma and allergic rhinitis and may modify the course of the disease. SIT is typically recommended for children whose asthma and allergic rhinitis symptoms cannot be adequately controlled with medication or environmental changes.
The US Food and Drug Administration has approved the use of allergen extracts for subcutaneous immunotherapy (SCIT) to treat allergic rhinitis and allergic asthma. Considerable interest has developed in using sublingual immunotherapy (SLIT), which is currently prescribed off-label in the United States. SLIT involves placement of the allergen under the tongue for local absorption, to desensitize the allergic individual over a period of months to years; this method has gained favor in Europe, 3 where sublingual tablets and aqueous immunotherapy have been approved.
The objective of the current systematic review was to summarize the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis. This review evaluated only the SCIT allergen formulations that are currently available in the United States or SLIT formulations with similar off-label substitutes. This report is derived from a comparative effectiveness review evaluating SIT in adult and pediatric populations commissioned by the US Agency for Healthcare Research and Quality (AHRQ).
METHODS
Technical experts were recruited for input on the research questions and search strategy. We developed a protocol for this review and posted it online, following guidelines for systematic review (http://effectivehealthcare.ahrq. gov/ehc/products/270/665/SIT_Protocol_ 20110824.pdf). Additional details on the methods appear in the full AHRQ Evidence Report, Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma, Comparative Effectiveness Review (http:// effectivehealthcare.ahrq.gov/searchfor-guides-reviews-and-reports/?pageaction=displayproduct&productid= 665).
Data Sources and Selection
We searched Medline, Embase, LILACS, CENTRAL, and the Cochrane Central Register of Controlled Trials, from inception through May 21, 2012 (Supplemental Appendix Fig 1) . Two investigators independently reviewed titles, abstracts, and full articles for possible inclusion. Disagreements were resolved by consensus. We included randomized controlled trials (RCTs), exclusively studying children with allergic asthma and/ or rhinoconjunctivitis due to inhalant allergens, with diagnoses confirmed by using objective testing (positive result on skin allergy testing and/or in vitro specific immunoglobulin E allergy testing) (Supplemental Appendix Table 1) . We included only studies evaluating SCIT formulations available in the United States or SLIT formuations with close off-label substitutes, alone or in combination with usual care, and compared them with placebo, pharmacotherapy, or other SIT regimens. Studies of sublingual tablets were not included because this formulation is currently not available for clinical use in the United States. We included only trials that clearly reported allergen dosages, evaluated clinical outcomes or safety, and were published in English.
Data Extraction and Quality Assessment
One investigator extracted data into standardized forms, and accuracy was confirmed by a second reviewer. We used DistillerSR for data management (Evidence Partners, Ottawa, Ontario, Canada). Data from the final time point were reported. For outcomes with multiple measurements during a single season, data collected at peak allergen season were used.
The quality of each study was assessed by using a modified Cochrane Collaboration Tool for Assessing Risk of Bias to record the adequacy of randomization, allocation concealment, blinding, completeness of data reporting, sponsor company involvement, and other sources of potential bias. 4 Two independent reviewers assigned ratings of low, medium, or high risk of bias based on this assessment. Disagreements were resolved by consensus.
Data Synthesis and Analysis
Data were stratified according to outcome, intervention, and allergen, and synthesized qualitatively. We graded the quantity, quality, and consistency of the evidence by adapting an evidencegrading scheme recommended by the Guide for Conducting Comparative Effectiveness Reviews. 5 The magnitude of effect was classified according to the percent difference in pre-to-post change comparing the SIT group and comparator group: ,15% was defined as a weak difference; a 15% to 40% difference was defined as moderate; and .40% was defined as a strong effect (Supplemental Appendix Table 2 ). The body of evidence for each primary outcome was graded as high, moderate, low, or insufficient (Supplemental Appendix Table 3 ). The evidence grade reflects the likelihood that additional research will change the conclusions about the intervention. Adverse events were categorized as local or systemic. Only studies that observed adverse events were included in the safety evaluation.
RESULTS
Our search generated 7746 citations (Fig 1) . We included 34 articles relevant to children: 13 trials of SCIT, 18 trials of SLIT, and 3 trials comparing SCIT with SLIT. The findings are summarized according to intervention and outcomes (Table 1) . We describe asthma findings only for studies that confirmed asthma diagnoses by using objective measures or previously established guidelines. Five of the included studies were not graded because all study arms received immunotherapy. [6] [7] [8] [9] [10] Study and Population Characteristics for SCIT Thirteen studies including 920 children aged 3 to 18 years evaluated SCIT for clinical outcomes. The primary diagnosis was asthma in 7 studies, 6, 7, [11] [12] [13] [14] [15] rhinoconjunctivitis in 1 study, 16 and asthma with rhinitis/rhinoconjunctivitis in 5 studies. 8, 9, [17] [18] [19] The majority of studies used a single allergen for SCIT. Dust mites were evaluated in 8 of the 13 studies. All studies allowed either routine medications or rescue medications. The maintenance dosing interval varied from biweekly dosing to dosing every 6 weeks, and the duration of treatment ranged from 4 months to 3 years. There was great heterogeneity in the allergen dose delivered and the reporting of dosage units.
Clinical Outcomes of SCIT in Children

Asthma
Six RCTs with 550 subjects evaluated SCIT for control of asthma symptoms relative to placebo 11, 15, 18, 19 or pharmacotherapy 13, 17 (Table 1 ; Supplemental Appendix Table 4 ). Four studies evaluated a single allergen 11, 13, 18, 19 and 2 used multiple allergens. 15, 17 Singleallergen SCIT studies demonstrated improvement in asthma symptoms, compared with placebo or pharmacotherapy, with moderate to strong magnitudes of effect. In contrast, 1 study with a low risk of bias enrolled 121 children with moderate to severe asthma already receiving appropriate asthma medications and found no improvement, compared with placebo, with SCIT using multiple allergens. 15 The overall strength of evidence is moderate that SCIT using a single allergen improves asthma symptoms relative to placebo or pharmacotherapy. However, there is low-grade evidence that SCIT using multiple allergens does not improve asthma symptoms in subjects with moderate to severe asthmatics.
Four studies with 470 participants evaluated SCIT for improvement of asthma medication usage (Supplemental Appendix Table 5 ), 11, 13, 15, 17 and 2 studies with 80 participants evaluated combined asthma and rhinitis/rhinoconjunctivitis medication usage (Supplemental Appendix Table 6 ). 18, 19 Four single-allergen studies demonstrated greater reduction in medication usage for asthma with or without rhinoconjunctivitis in the SCIT group than in the comparator. 11, 13, 18, 19 One study with 121 participants and The total number of articles excluded may be exceeded by the number of reasons for exclusion, because articles were excluded by 2 reviewers at this level. b Other reasons: control group is healthy population, routes of administration not included (eg, oral, nasal, lymph node), abandoned interventions, outcomes not reported, no comparator group, continued medical education reports, editorials or reviews, studies about mechanism of action, other allergies (food, aspirin), study in animals or in vitro, or #6 patients per arm. 
SCIT Both studies reported significant improvement in disease-specific QoL in the SCIT arm Low that SCIT improves rhinoconjunctivitis quality of life more than comparators
Multiple (1) vs placebo (1) vs pharmacotherapy (1) SLIT studies Asthma symptoms 9 471 Dust mite (7) SLIT All 9 studies demonstrated improvement in the SLIT group. Higher dose of SLIT showed greater improvement compared with lower dose/placebo.
There was a strong magnitude of effect in 6 studies. High that SLIT improves asthma symptoms more than comparators Tree mix (1) vs placebo ( SLIT 11 studies showed greater improvement in symptoms with SLIT. One placebo controlled study found no improvement in symptoms.
Moderate that SLIT improves rhinitis or rhinoconjunctivitis symptoms more than comparators Dust mite (6) vs placebo (10)
Olive (1) vs SLIT (1) (high-vs low-dose vs placebo) (2) SLIT vs placebo 4 studies showed greater improvement in symptoms in the SLIT group compared with placebo. Higher dose showed greater improvement. The direction of change could not be determined in one study.
Moderate that SLIT improves conjunctivitis symptoms more than comparators
Olive (1) vs placebo (4)
Tree mix (1) vs SLIT (1) (high-vs low-dose vs placebo)
Medication use 13 1078 Dust mite (6) SLIT 11 studies showed a reduction in medication use in the SLIT group; 1 study showed no difference between SLIT and placebo. The direction of change could not be determined in one study. There was a moderate or strong magnitude of effect in 6 studies.
Moderate that SLIT improves medication use more than comparators Grass mix (2) vs placebo (11)
Olive (1) Tree mix (1) Multiple (1) low risk of bias showed similar reductions in asthma medication use in both the SCIT and placebo groups. 15 The strength of evidence is low that SCIT improves medication use for asthma or combined asthma and rhinoconjunctivitis.
Two studies with 85 participants evaluated SCIT for improvement on a combined symptom and medication score ( Table 1 ; Supplemental Appendix Table 7 ). 12, 19 Both studies showed greater improvement in the SCIT group compared with placebo. The strength of evidence is low that SCIT improves combined symptom and medication scores.
Rhinitis
Three placebo-controlled trials with 285 subjects evaluated SCIT for control of rhinitis and rhinoconjunctivitis symptoms (Table 1; Supplemental Appendix  Table 8 ). 16, 18, 19 These included singleand multiple-allergen regimens. Two studies allowed conventional therapy, 16, 18 and 1 study allowed only rescue therapy in the treatment arms. 19 The largest study, with 205 participants and a medium risk of bias, strongly favored SCIT with grass/birch mix along with conventional therapy over placebo. 16 The second study, with 50 participants and medium risk of bias, moderately favored SCIT over placebo. 19 The smallest study, with 30 participants and a low risk of bias, weakly favored SCIT over placebo. 18 Overall, we found moderate-strength evidence that SCIT controls rhinitis and rhinoconjunctivitis symptoms in children better than placebo.
Conjunctivitis
Three placebo-controlled trials with 285 participants evaluated SCIT, compared with placebo, for control of conjunctivitis symptoms (Table 1 ; Supplemental Appendix Table 9 ). 16, 18, 19 Risk of bias was low to medium. One study with a medium risk of bias and 205 participants reported significant improvement in conjunctivitis symptom scores, although actual scores were not reported. 16, 19 Kuna et al 19 also found significant improvement in symptoms, with strong magnitude of effect, after 3 years of SCIT. The third study, with 30 participants and low risk of bias, revealed no significant improvement in conjunctivitis symptoms. 18 The strength of evidence is low that SCIT improves conjunctivitis symptoms.
Other Outcomes
Quality of life (QoL) was evaluated in 2 studies (Table 1 ; Supplemental Appendix Table 10 ). 17, 19 One study with 50 participants and medium risk of bias demonstrated a significant improvement in QoL scores after 3 years of SCIT in children and adolescents with asthma and rhinitis, as well as in the parents of children receiving SCIT. 19 Another study with 300 participants and a high risk of bias reported no significant difference in QoL with SCIT compared with placebo. 17 Prevention of asthma was evaluated in 1 study. Möller et al 16 investigated asthma prevention as a primary outcome and observed, among 151 children with allergic rhinoconjunctivitis without asthma, a 2.5-fold greater odds of preventing new onset of asthma after 3 years of SCIT versus placebo. Benefit persisted after 5 years and after 10 years. 20, 21 Safety of SCIT in Children
Adverse events were observed in 10 of the 13 studies. [6] [7] [8] 12, 14, [17] [18] [19] Local reactions (injection site redness and swelling) were common in both the SCIT and placebo arms, occurring in up to 54% of SCIT and 53% of placebo injections in 1 study ( 
Clinical Outcomes of SLIT in Children
Asthma
Nine studies including 471 participants evaluated SLIT for control of asthma symptoms (Table 1; Supplemental Appendix Tables 11 and 12) . [22] [23] [24] [32] [33] [34] [35] 37, 38 Seven studies evaluated dust mite allergen. [22] [23] [24] [32] [33] [34] 38 The SLIT-treated children in the placebo-controlled studies demonstrated moderate to strong improvement in asthma symptoms. The risk of bias was low in 3 studies. 22, 32, 34 Therefore, the strength of evidence is high that SLIT improves asthma symptoms, compared with placebo.
Rhinitis
Twelve trials including 1065 children evaluated SLIT for control of rhinitis or Grass mix (1) Mild (1%) Trees (1) Severe ( rhinoconjunctivitis symptoms (Table 1 ; Supplemental Appendix Table 13 ). [25] [26] [27] [28] [29] [32] [33] [34] [35] [36] [37] [38] One-half of the studies evaluated dust mite allergens. 25, 26, [32] [33] [34] 38 Risk of bias was low in 4 studies, 27, 29, 32, 34 medium in 6 studies, 26, 33, [35] [36] [37] [38] and high in 2 studies. 25, 28 Five studies demonstrated significant improvement in rhinitis/ rhinoconjunctivitis scores with SLIT, compared with placebo, with moderate to strong magnitudes of effect. 33, 34, [36] [37] [38] Four studies did not show significant improvement with SLIT, 25, 26, 29, 32 and 1 of these favored placebo. 26 The strength of evidence is moderate that SLIT improves rhinitis symptoms.
Conjunctivitis
Five RCTs including 513 participants evaluated SLIT for control of conjunctivitis symptoms (Table 1; Supplemental  Appendix Table 14) . 25, [34] [35] [36] [37] Two placebocontrolled trials of olive and tree mix allergens with medium risk of bias that enrolled 70 and 98 children, respectively, demonstrated moderate to strong magnitude of effect for SLIT. 36, 37 One study of dust mite immunotherapy in 58 children, with a low risk of bias and weak magnitude of effect, showed little improvement with SLIT compared with placebo. 34 One study of dust mite allergen with 257 children and a high risk of bias and another study of Parietaria allergen with 30 children and a low risk of bias reported improvement with SLIT, although we could not determine the magnitude of effect. 25, 35 The strength of evidence is moderate that SLIT improves conjunctivitis symptoms.
Medication Scores
Medication scores were reported in 13 studies with 1078 participants (Table 1; Supplemental Appendix  Table 15 ). [22] [23] [24] [25] [26] [27] [28] [29] 32, 33, [35] [36] [37] Six studies evaluated dust mite allergen. [22] [23] [24] [25] [26] 32 The placebo-controlled studies demonstrated significant reductions in medication use in the SLIT group relative to the placebo group, with moderate to strong magnitudes of effect in patients with asthma and/or rhinitis. The magnitudes of effect could not be determined in 7 studies. 25, [27] [28] [29] 32, 35, 36 The risk of bias across these studies was mixed. The strength of evidence is moderate that SLIT decreases medication use.
Other Outcomes
Combined symptom plus medication scores were reported in 2 SLIT trials with 329 participants (Table 1 ; Supplemental Appendix Table 16 ). 28, 31 Symptom scores included nasal, eye, and bronchial symptoms. One study of 216 participants with asthma and rhinitis and a medium risk of bias showed a strong effect, with lower scores on the symptom and medication use measure with SLIT than with conventional care. 31 One study of grass mix allergen that included 113 children with rhinoconjunctivitis and had a high risk of bias reported no significant difference between SLIT and conventional therapy, although the magnitude of effect could not be determined. 28 The strength of evidence is low that SLIT decreases the combination of symptoms and medication use for asthma and rhinitis.
QoL was reported in 2 studies involving 461 participants; QoL was measured by using the Pediatric and Adolescent Rhinoconjunctivitis Quality of Life questionnaires (Table 1 ; Supplemental Appendix Table 17 ). 25, 29 One study reported no improvement in QoL, 29 and another reported no difference between the SLIT and placebo groups after 2 years. 25 There is insufficient evidence to evaluate the impact of SLIT on disease-specific QoL.
Disease modification was addressed in 3 studies. 24, 27, 31 Niu et al 24 found significantly more patients with improved asthma classification from mild/moderate persistent asthma to mild intermittent asthma after 6 months of SLIT with dust mite allergen, compared with placebo. Marogna et al 31 found no significant difference in the percentage of children with mild intermittent asthma after 3 years of SLIT, compared with placebo. La Rosa et al 27 also found no difference in rhinitis symptoms during Parietaria pollen season after 8 years of follow-up in the SLIT and placebo groups.
Prevention of asthma was addressed in 3 studies. 27, 28, 31 Novembre et al 28 found that children receiving conventional therapy had a 3.8-fold increased risk of developing asthma compared with those receiving SLIT for 3 years. Marogna et al 31 found a lower occurrence of new mild, persistent asthma in patients receiving SLIT compared with a conventional-therapy group after 3 years. La Rosa et al 27 found no difference, after treatment for 2 years, in the number of patients with asthma in the SLIT versus placebo groups at 8 years of follow-up.
Two studies addressed the development of new sensitivities. 27, 31 Marogna et al 31 found a 40% decreased odds of developing new sensitivities after 3 years of SLIT, compared with pharmacotherapy. La Rosa et al 27 found no difference in the number of new sensitizations in monosensitized children treated with SLIT, compared with placebo, after 8 years of follow-up.
Safety of SLIT in Children
Local reactions, such as oral itching and swelling, were common but mild (Table 2). Twelve studies reported local reactions in 0.2% to 50% of patients receiving SLIT and 6% to 25% of patients receiving placebo. 22, 25, [27] [28] [29] [30] [31] [35] [36] [37] Systemic reactions were commonly reported in both the SLIT and placebo groups, but no life-threatening reactions, anaphylaxis, or deaths were reported in these trials. to least commonly reported, the symptoms or reactions were characterized as general, gastrointestinal, ocular, respiratory, and cutaneous. Although severe systemic reactions were rare, 1 study reported severe rhinitis and severe asthma symptoms in children who exceeded their maximum dose. 34 These adverse events resolved when the children returned to a lower dose.
Study and Population
Characteristics: SCIT Versus SLIT Three RCTs of dust mite immunotherapy reported on the efficacy and safety of SCIT, compared head-to-head with SLIT in children. [39] [40] [41] These 3 studies included 135 children, 5 to 14 years of age, with a primary diagnosis of asthma with rhinitis. One study allowed the use of conventional medications, 39 and 2 studies allowed only rescue medications. 40, 41 The maintenance dose for SCIT ranged from thrice weekly to monthly; for SLIT, it was thrice weekly in all studies. Treatment duration in each study was 1 year.
Comparison groups in the studies included SCIT, SLIT, SCIT plus SLIT, and placebo or pharmacotherapy arms. All 3 studies had medium risks of bias. Table 20 ). 40 Because of the inconsistent direction of change and the few studies available, the strength of evidence is low to support a greater decrease in asthma symptoms, rhinitis symptoms, and medication use with SCIT compared with SLIT.
Clinical Outcomes of SCIT Versus SLIT
Safety of SCIT Versus SLIT
Among these 3 studies, local injection site reactions were reported in 3 patients receiving SCIT, and local reactions (oral itching) were reported in 3 patients receiving SLIT (Table 2) . [39] [40] [41] No systemic reactions were reported in patients receiving SLIT. Among 37 patients receiving SCIT, 4 experienced systemic reactions, including 1 anaphylaxis event and 3 patients with moderate to severe respiratory symptoms. These studies suggest that SLIT may be safer than SCIT.
DISCUSSION
In this comprehensive, systematic review of SIT for children with asthma and allergic rhinitis, we summarized data from 34 RCTS, including 13 testing SCIT, 18 testing SLIT, and 3 comparing SCIT with SLIT. We found moderate-strength evidence that SCIT improves asthma and rhinitis symptoms and low-strength evidence that SCIT improves conjunctivitis symptoms, lowers asthma medication scores, and improves rhinoconjunctivitis QoL. We found high-strength evidence that SLIT improves asthma symptoms and moderate-strength evidence that SLIT improves rhinitis and conjunctivitis symptoms and decreases medication usage. We found low-strength evidence to support SCIT over SLIT for improving asthma or rhinitis symptoms or medication usage. Local and systemic reactions were common with both regimens.
Anaphylaxis was reported with SCIT in 1 study comparing SCIT with SLIT, and no deaths were reported.
Few previous systematic reviews have evaluated the efficacy of SCITexclusively in children. Improvements in allergic rhinitis symptoms and medication use, and asthma symptoms and medication use, have been reported with SCIT in previous reviews of combined adult and pediatric populations, without separate pediatric results. 42, 43 Another systematic review reported conflicting results regarding the clinical efficacy of SCIT for allergic rhinoconjunctivitis in children. 44 Our review of SLIT in children expands on the findings of previous pediatric systematic reviews. Significant reductions in asthma symptoms and medication use with SLIT were similarly reported in previous reviews. 45, 46 For allergic conjunctivitis symptoms, 1 review of 9 studies similarly showed significant reductions in children treated with SLIT, 47 whereas another review of 7 studies found no significant reductions in conjunctivitis symptoms. 46 In contrast, several reviews did not find significant reductions in rhinitis or rhinoconjunctivitis symptoms or medication use in children treated with SLIT, 46, 48, 49 although decreasing trends were observed in 1 review. 46 Our systematic review found more evidence to support the use of SLIT than SCIT. This finding may reflect the fact that there are fewer studies evaluating SCIT exclusively in children, and few head-to-head comparisons of SCIT and SLIT. Additional studies directly comparing these 2 modes of delivery or combination regimens may strengthen this evidence base.
Our safety results are consistent with previous studies evaluating SCIT and SLIT, both of which have been shown to be safe in children with allergic rhinitis and mild asthma. Adverse events associated with SCIT include local discomfort, pain, and serious reactions such as rare fatal and near-fatal reactions. [50] [51] [52] Most adverse events reported with SLIT have been local reactions of the oral mucosa, with few serious systemic reactions. Only a few cases of anaphylaxis have been reported in children receiving SLIT, although none was found in our review. [52] [53] [54] One important benefit of SIT specific to children may be the potential to modify the response to allergens at an early stage and thus prevent disease progression. 16, 20, 21, 24, 28, 31 SIT is currently the only treatment with this potential to modify and prevent progression of disease from allergic rhinitis to asthma. 52 However, our study found few reports to support SCIT and SLIT for preventing the development of asthma and new sensitizations in children.
Challenges and Study Limitations
Our review involves several challenges and limitations. There was considerable heterogeneity in the study allergens, dosages, dose units, duration of treatment, and in reporting and scoring of outcomes and safety data. This heterogeneity precluded quantitative pooling of the data and made data synthesis challenging. The RCTs that were included in the review varied in their quality. Several studies had moderate or high risk of bias because they did not specify whether allocation schemes were concealed or if the intervention was concealed from the participants and outcome assessors, or did not clarify the role of industry support or sponsors. The majority of SCIT studies were single allergen, and thus the results cannot necessarily be generalized to the use of multipleallergen regimens, which is common in the United States. In contrast, the SLIT studies mostly used multiple allergens, and the results are not necessarily generalizable to single-allergen regimens. Safety data were variably reported and only reflect observed reports from RCTs. A more complete evaluation of safety would require inclusion of data from observational studies. Publication bias may also be a concern because we only included studies published in English. Although we requested unpublished data from pharmaceutical companies, we did not receive any information.
Applicability
Our study findings are applicable to children and adolescents with allergic rhinoconjunctivitisorasthma.Ourresults are relevant to patients making decisions about therapy based on efficacy and safety of SIT, clinicians who provide care for children with asthma and allergic rhinitis, guideline developers making recommendations on SIT in children, and researchers evaluating SIT in children.
CONCLUSIONS
The evidence provides support for the efficacy of both SCIT and SLIT for treatment of allergic rhinitis and asthma in children. The evidence base is stronger for SLIT than for SCIT, which may reflect the fact that there are fewer studies evaluating SCIT exclusively in children and few head-to-head comparisons of SCIT and SLIT. SLIT has been thought to be a favorable alternative to SCIT, especially for children, based on convenience and ease of administration at home without multiple injections, 55 whereas SCIT requires administration by an experienced provider. These benefits may influence the tolerability and adherence to treatment, especially in children, but this outcome remains to be seen. Additional studies directly comparing these 2 modes of delivery or combination regimens may strengthen this evidence.
Future pediatric studies should evaluate the real-world effectiveness of SCIT and SLIT, addressing issues of compliance, which are especially relevant in children. In addition, direct comparisons of SCIT versus SLIT should evaluate longterm outcomes such as prevention of asthma and potential for disease modification. Evaluating the differential effects of immunotherapy based on the developmental stage of children and adolescents can help to optimize treatment and identify the optimal dose, frequency, treatment duration, and age for initiating treatment in children.
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